Sex- and brain region-specific role of cytochrome c oxidase in 1-methyl-4-phenylpyridinium-mediated astrocyte vulnerability

Journal of Neuroscience Research

Volumn 89, Issue 12, 2011, Pages 2068-2082

  Sundar Boyalla, Syama ^a   Barbara Victor, Marion ^a   Roemgens, André ^a   Beyer, Cordian ^a   Arnold, Susanne ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Midbrain; Mitochondria; Oxidative stress; Parkinson's disease; Sex differences

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME C OXIDASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENERGY YIELD; FEMALE; MALE; MESENCEPHALON; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; ASTROCYTES; BLOTTING, WESTERN; BRAIN; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HERBICIDES; ISOENZYMES; MALE; MICE; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS;

EID: 80053632127     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22669     Document Type: Article

References (45)

1. Andreyev AY, Kushnareva YE, Starkov AA. 2005. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Moscow) 70: 200-214.
2. Araújo GW, Beyer C, Arnold S. 2008. Oestrogen influences on mitochondrial gene expression and respiratory chain activity in cortical and mesencephalic astrocytes. J Neuroendocrinol 20: 930-941.
3. Arnold S, Kadenbach B. 1997. Cell respiration is controlled by ATP, an allosteric inhibitor of cytochrome c oxidase. Eur J Biochem (FEBS J) 249: 350-354.
4. Arnold S, Kadenbach B. 1999. The intramitochondrial ATP/ADP-ratio controls cytochrome c oxidase activity allosterically. FEBS Lett 443: 105-108.
5. Arnold S, de Araújo GW, Beyer C. 2008. Gender-specific regulation of mitochondrial fusion and fission gene transcription and viability of cortical astrocytes by steroid hormones. J Mol Endocrinol 41: 289-300.
6. Banerjee R, Starkov AA, Beal MF, Thomas B. 2009. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792: 651-663.
7. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455.
8. Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson's disease. Bioessays 24: 308-318.
9. Cadenas E, Boveris A, Ragan CI, Stoppani AO. 1977. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch Biochem Biophys 180: 248-257.
10. Chao CC, Hu S, Peterson PK. 1996. Glia: the not so innocent bystanders. J Neurovirol 2: 234-239.
11. + treatment in human astrocytoma U373MG cells. J Pineal Res 36: 117-125.
12. Ciesielska A, Joniec I, Kurkowska-Jastrzebska I, Cudna A, Przybyłkowski A. 2009. The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 58: 747-753.
13. Dluzen DE, McDermott JL. 2000. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease. J Gender Specific Med 3: 36-42.
14. Dröse S, Brandt U. 2008. The mechanism of mitochondrial superoxide production by cytochrome bc1 complex. J Biol Chem 283: 21649-21654.
15. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, Larsson NG. 2007. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 104: 1325-1330.
16. Fahn S, Sulzer D. 2004. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1: 139-154.
17. Folbergrová J, Ješina P, Haugvicová R, Lisý V, Houštěk J. 2010. Sustained deficiency of mitochondrial complex I activity during long periods of survival after seizures induced in immature rats by homocysteic acid. Neurochem Int (in press).
18. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW. 2007. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 78: 819-824.
19. He XJ, Nakayama H, Dong M, Yamauchi H, Ueno M, Uetsuka K, Doi K. 2006. Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease. J Neuropathol Exp Neurol 65: 873-882.
20. Horvat S, Beyer C, Arnold S. 2006. Effect of hypoxia on the transcription pattern of subunit isoforms and the kinetics of cytochrome c oxidase in cortical astrocytes and cerebellar neurons. J Neurochem 99: 937-951.
21. Huerta C, Castro MG, Coto E, Blázquez M, Ribacoba R, Guisasola LM, Salvador C, Martínez C, Lahoz CH, Alvarez V. 2005. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J Neurol Sci 236: 49-54.
22. Jenner P, Olanow WC. 1996. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-S170.
23. Kadenbach B, Arnold S. 1999. A second mechanism of respiratory control. FEBS Lett 447: 131-134.
24. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A. 1998. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Immunopharmacology 39: 167-180.
25. Marella M, Seo BB, Nakamaru-Ogiso E, Greenamyre JT, Matsuno-Yagi A, Yagi T. 2008. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS ONE 3: e1433.
26. Marsden CD. 1990. Parkinson's disease. Lancet 335: 948-952.
27. McGeer PL, McGeer EG. 2008. Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
28. Misiak M, Beyer C, Arnold S. 2010a. Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons. Biochem Biophys Acta 1797: 1178-1188.
29. Misiak M, Singh S, Drewlo S, Beyer C, Arnold S. 2010b. Brain region-specific vulnerability of astrocytes in response to 3-nitropropionic acid is mediated by cytochrome c oxidase isoform expression. Cell Tiss Res 341: 83-93.
30. Pellerin L. 2003. Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem Int 43: 331-338.
31. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, Vila M. 2005. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 102: 19126-19131.
32. Przedborski S, Vila M. 2003. The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991: 189-198.
33. Ramsay RR, Singer TP. 1992. Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piercidin A, and MPP1. Biochem Biophys Res Commun 189: 47-52.
34. Rankin S, Rozengurt E. 1994. Platelet-derived growth factor modulation of focal adhesion kinase (p125FAK) and paxillin tyrosine phosphorylation in Swiss 3T3 cells. Bell-shaped dose response and cross-talk with bombesin. J Biol Chem 269: 704-710.
35. Roemgens A, Singh S, Beyer C, Arnold S. 2010. Inducers of chemical hypoxia act in a gender- and brain region-specific manner on primary astrocyte viability and cytochrome c oxidase. Neurotox Res doi: 10.1007/s12640-010-9213-z.
36. Saikumar P, Ramakrishna Kurup CK. 1985. Effect of administration of 2-methyl-4-dimethylaminoazobenzene on the half-lives of rat liver mitochondria and cytochrome c oxidase. Biochim Biophys Acta 840: 127-133.
37. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827.
38. Simpkins JW, Yi KD, Yang SH, Dykens JA. 2009. Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta doi:10.1016/j.bbagen.2009.11.013.
39. Singh S, Misiak M, Beyer C, Arnold S. 2009. Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes. Glia 57: 1480-1491.
40. Singh S, Misiak M, Beyer C, Arnold S. 2010. Brain region specificity of 3-nitropropionic acid-induced vulnerability of neurons involves cytochrome c oxidase. Neurochem Int 57: 297-305.
41. van den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. 2003. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157: 1015-1022.
42. Villani G, Greco M, Papa S, Attardi G. 1998. Low reserve of cytochrome c oxidase capacity in vivo in the respiratory chain of a variety of human cell types. J Biol Chem 273: 31829-31836.
43. White RJ, Reynolds IJ. 1996. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 16: 5688-5697.
44. +: Selective vulnerability of cultured mouse astrocytes. Brain Res 836: 237-244.
45. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. 2004. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 75: 637-639.